AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.07B
1-Year Est. Return
86.9%
1 Year Est. Return
+86.9%
AUM
$676M
AUM Growth
+$37.5M
(+5.9%)
Holding
109
Top Buys
| 1 | +$33.7M | |
| 2 | +$32M | |
| 3 | +$9.71M | |
| 4 |
Lexeo Therapeutics
LXEO
|
+$8.48M |
| 5 |
Enliven Therapeutics
ELVN
|
+$8.02M |
Top Sells
| 1 | +$19.9M | |
| 2 | +$16.8M | |
| 3 | +$13.3M | |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$8.5M |
| 5 |
INZY
Inozyme Pharma
INZY
|
+$8.47M |
Sector Composition
| 1 | Healthcare | 95.02% |
| 2 | Financials | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRML
101
DELISTED
Tourmaline Bio
TRML
| – | – |
0
|
|
||
102
Viking Therapeutics
VKTX
$4.42B
| – | – |
-25,000
|
|
||
103
State Street SPDR S&P Biotech ETF
XBI
$6.6B
| – | – |
0
|
|
||
|
MBX
104
MBX Biosciences
MBX
$1.11B
| – | – |
-175,000
|
|
||
|
MAZE
105
Maze Therapeutics
MAZE
$1.57B
| – | – |
-250,000
|
|